EUVIMEDEUVIMED entdecken
Crossref

Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma

Alaa S Hrizat, Ruihe Lin, Jaime Eberle-Singh, Raymond O'Neill, Yan Xia, Joseph R Testa, Robert Uzzo, Peter A McCue, Haifeng Yang, Li Li

Pathology - Research and Practice · 2025

DOI: 10.1016/j.prp.2024.155774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2025. Verfasst von Alaa S Hrizat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States. Electronic address: alaa.s.hriza…. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with clear cell renal cell carcinoma (ccRCC) metastases face poor prognoses, even with adjuvant therapies. Tumor-infiltrating T-cells and macrophages are critical in targeting tumor cells within the renal microenvironment. Beyond VHL mutations, loss-of-function mutations in SWI/SNF complex genes, including PBRM1, BAP1, ARID1A, SETD2, SMARCA4 (BRG1), and SMARCA2 (BRM), have been implicated in ccRCC progression. DESIGN: A tissue microarray of 160 ccRCC cases was analyzed via immunohistochemistry (IHC) for SWI/SNF protein expression and CD4 + /CD8 + T-cell infiltration. Clinical and pathologic features were obtained through electronic medical records. Statistical analyses included one-way ANOVA, two-way ANOVA, Pearson's chi-square and t-tests. RESULTS: Loss of SWI/SNF protein expression was observed in PBRM1 (31 %), ARID1A (51 %), SETD2 (14 %), BRG1 (15 %), BRM (38 %), and BAP1 (40 %). T-cell counts varied significantly with stage: CD4 + counts peaked at Stage 3, while CD8 + counts increased through Stage 4 (p < 0.001). Loss of PBRM1 was more frequent in advanced stages (29.4 %, p < 0.001), while BRM and BRG1 losses were more common in earlier stages (p < 0.001, p = 0.006). ARID1A and BRM losses correlated with reduced CD8 + counts (p = 0.016, p = 0.032) and stage-specific CD4 + variations (p < 0.001, p = 0.042). CONCLUSION: Loss of PBRM1, SMARCA2/BRM, and SMARCA4/BRG1 expression is significantly associated with ccRCC progression, with PBRM1 loss prevalent in advanced stages and SMARCA2/BRM and SMARCA4/BRG1 in earlier stages. ARID1A and SMARCA2/BRM losses correlate with reduced CD8 + counts and stage-specific CD4 + infiltration, highlighting their potential as biomarkers for disease progression and immunotherapeutic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingCarcinoma, Renal CellKidney NeoplasmsHumansFemaleMaleMiddle AgedAgedTranscription FactorsAdultBiomarkers, TumorAged, 80 and overDNA HelicasesNuclear ProteinsDNA-Binding Proteins

Stichwörter der Autor:innen

Clear cell renal cell carcinomaSWI/SNF genesTumor immune microenvironment

Substanzen

Transcription FactorsBiomarkers, TumorDNA HelicasesPBRM1 protein, humanNuclear ProteinsSMARCA4 protein, humanARID1A protein, humanSMARCA2 protein, humanDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States. Electronic address: alaa.s.hrizat@gmail.com.
  • Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States.
  • Department of Laboratories, Arnot Ogden Medical Center, Elmira, NY, United States.
  • Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, United States.
  • Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States.
  • Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States; Physician Sciences Medical Group, Norfolk General Hospital, Norfolk, VA, United States.

Zitieren

APA

Hrizat, A. S., Lin, R., Eberle-Singh, J., O'Neill, R., Xia, Y., Testa, J. R., Uzzo, R., McCue, P. A., Yang, H., & Li, L. (2025). Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155774

Vancouver

Hrizat AS, Lin R, Eberle-Singh J, O'Neill R, Xia Y, Testa JR, et al. Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma. Pathology - Research and Practice. 2025. doi:10.1016/j.prp.2024.155774

BibTeX
@article{Hrizat2025,
  author = {Hrizat, Alaa S and Lin, Ruihe and Eberle-Singh, Jaime and O'Neill, Raymond and Xia, Yan and Testa, Joseph R and Uzzo, Robert and McCue, Peter A and Yang, Haifeng and Li, Li},
  title = {Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma},
  journal = {Pathology - Research and Practice},
  year = {2025},
  doi = {10.1016/j.prp.2024.155774}
}
Kostenlos starten →